Ginwa Enterprise Group Inc (600080.SS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE000000QQ8

Price
3.88 CNY
Market cap
1.45 bn CNY
P/E (2025)
92.98
P/S (2025)
2.66
Dividend yield
0.00 %
Net margin
2.86 %
Return on equity (ROE)
1.00 %
Return on assets (ROA)
0.81 %

Ginwa Enterprise Group Inc financials

Fiscal year20242025
Revenue585.46 m CNY544.04 m CNY
Gross profit458.39 m CNY418.92 m CNY
Operating income49.02 m CNY5.32 m CNY
EBIT48.30 m CNY23.37 m CNY
Net income74.61 m CNY15.58 m CNY
Diluted EPS – continuing operations0.21 CNY0.04 CNY

Full history since 1994, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Ginwa Enterprise Group Inc

Ginwa Enterprise (Group) Inc. researches, develops, produces, markets, and sells traditional Chinese medicines, biological drugs, and chemical drugs primarily in China. The company offers a range of orthopaedics, immunity, children, and general medicines in various dosage forms, including tablets, capsules, powders, mixtures, oral solutions, syrups, and external solutions. It is also involved in the pharmaceutical logistics activities. The company was founded in 1996 and is headquartered in Xi'an, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.